Anokion
Signal active
Organization
Contact Information
Overview
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
About
Industries
Biotechnology, Therapeutics, Clinical Trials
Founded
2010
Employees
11-50
Headquarters locations
Switzerland, Europe
Social
N/A
Profile Resume
Anokion headquartered in Switzerland, Europe, operates in the Biotechnology, Therapeutics, Clinical Trials sector. The company focuses on Biotechnology and has secured $5.4B in funding across 48 round(s). With a team of 11-50 employees, Anokion is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Anokion, raised $37.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
5
Lead Investors
0
Total Funding Amount
$112.6M
Details
2
Anokion has raised a total of $112.6M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 40.0M | ||
| 2014 | Early Stage Venture | 37.5M |
Investors
Anokion is funded by 21 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Versant Ventures | - | FUNDING ROUND - Versant Ventures | 37.5M |
| Harry Welten | - | FUNDING ROUND - Harry Welten | 37.5M |
| Anokion | - | FUNDING ROUND - Anokion | 37.5M |
| André J. Mueller | - | FUNDING ROUND - André J. Mueller | 37.5M |
Recent Activity
There is no recent news or activity for this profile.